ArticleJournal of inherited metabolic disease2025
Audiovestibular Findings in Gaucher Disease Types I and III: Evidence of Vestibular Involvement in GD1.
Article in Journal of inherited metabolic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Lysosomal Storage to Neurodegeneration: Sphingolipid Signaling as a Driver of CNS Pathology and Biomarker Strategy in Neuronopathic Gaucher Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gaucher disease (GD), the most prevalent lysosomal storage disorder, is characterized by varying levels of systemic and neurological involvement. This study aims to investigate audiovestibular system involvement in patients with Gaucher disease type I (GD1) and type III (GD3) using audiometric and vestibular evaluations. We conducted a retrospective analysis of 42 patients diagnosed with GD who presented to the Department of Otorhinolaryngology at Çukurova University Faculty of Medicine between January 2001 and September 2023. The evaluations included pure tone audiometry (PTA), speech discrimination scores (SDS), acoustic impedance tests, and Video Head Impulse Test (vHIT) assessments. Of the 42 patients, 18 were diagnosed with GD1, and 24 with GD3. Audiovestibular anomalies were identified in 11 patients (26.2%). Sensorineural hearing loss (SNHL) was detected in 9 patients, including 4 GD1 and 5 GD3 patients, with bilateral involvement in 5 cases. The severity of hearing loss ranged from mild to moderately severe. Vestibular impairment, demonstrated by reduced vestibulo-ocular reflex (VOR) gain and catch-up saccades (CUS), was observed in 5 patients, predominantly among GD3 cases. Notably, concurrent audiovestibular dysfunction was observed in three patients, one with GD1 and two with GD3. This study is the first to describe the vestibular involvement in GD1. Audiovestibular abnormalities can manifest in both GD1 and GD3 patients, with distinct patterns of involvement. Regular auditory and vestibular assessments are essential to identify sensory deficits early, guide rehabilitation strategies, and enhance the quality of life for GD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.